Methods and compositions for in vivo gene therapy
First Claim
1. A method of introducing a nucleic acid into cells of a mammal, said method comprising introducing the nucleic acid into the mammal systemically, wherein:
- the nucleic acid is complexed to a lipid carrier comprising cationic lipids and a steroid, the carrier having a mean diameter of less than about 10 microns, resulting in a nucleic acid-lipid carrier complex;
the nucleic acid-lipid carrier complexes are substantially free of macroaggregates prior to said systemic introduction;
the nucleic acid to lipid carrier ratio is less than 6;
1 micrograms nucleic acid to nanomoles cationic lipid; and
the nucleic acid comprises a DNA expression cassette comprising a promoter and a DNA subsequence encoding a protein.
0 Assignments
0 Petitions
Accused Products
Abstract
Novel methods and compositions are provided for introducing a gene capable of modulating the genotype and phenotype into two or more tissues following systemic administration. The gene can be introduced into a mammalian host by way of an expression vector either as naked DNA or associated with lipid carriers, particularly cationic lipid carriers. Multiple individual tisssues can be transfected using naked DNA. Using a DNA: lipid carrier complex. multiple tissues and cell types can be transfected. The techniques and compositions find use in the palliation or treatment of any of a variety of genetic-based disorders.
-
Citations
38 Claims
-
1. A method of introducing a nucleic acid into cells of a mammal, said method comprising introducing the nucleic acid into the mammal systemically, wherein:
-
the nucleic acid is complexed to a lipid carrier comprising cationic lipids and a steroid, the carrier having a mean diameter of less than about 10 microns, resulting in a nucleic acid-lipid carrier complex;
the nucleic acid-lipid carrier complexes are substantially free of macroaggregates prior to said systemic introduction;
the nucleic acid to lipid carrier ratio is less than 6;
1 micrograms nucleic acid to nanomoles cationic lipid; and
the nucleic acid comprises a DNA expression cassette comprising a promoter and a DNA subsequence encoding a protein. - View Dependent Claims (2, 3, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)
-
-
4. A method of introducing a nucleic acid into a mammal, said method comprising introducing the nucleic acid into the mammal systemically, wherein:
-
the nucleic acid is complexed to a lipid carrier consisting essentially of cationic lipids and steroids, said carrier having a mean diameter of less than about 10 microns, wherein the molar ratio of cationic lipids to steroids ranges from about 1;
19 to about 1;
1, resulting in a nucleic acid lipid carrier complex;
the nucleic acid-lipid carrier complexes are administered in a form substantially free of macroaggregates;
the nucleic acid to lipid carrier ratio is less than 6;
1 micrograms nucleic acid to nanomoles cationic lipid; and
the nucleic acid comprises a DNA expression cassette comprising a promoter and a DNA subsequence encoding a protein.- View Dependent Claims (5, 6)
-
-
34. A mammalian transformation complex comprising:
-
a cationic lipid and a non-cationic lipid forming a lipid complex ranging in size from 100 nm to 10 microns in diameter;
combined with nucleic acid in a ratio of less than 6;
1 micrograms nucleic acid to nanomoles cationic lipid;
an excipient for in vivo systemic administration; and
,wherein said non-cationic lipid comprises cholesterol and said complex is substantially free of macroaggregates in vitro, the complex transforms a cell in vivo following systemic administration, and wherein the nucleic acid comprises a DNA expression cassette comprising a promoter and a DNA subsequence encoding a protein. - View Dependent Claims (35)
-
-
36. A method of making a nucleic acid:
- lipid complex for systemic administration to a mammal comprising;
mixing a nucleic acid and a lipid carrier to provide a non-aggregating nucleic acid;
lipid carrier complex having a mean diameter of less than about 10 microns, wherein the lipid carrier comprises cationic lipids and a steroid, the nucleic acid to lipid carrier ratio is less than 6;
1 micrograms DNA to nanomoles cationic lipid, and wherein the nucleic acid comprises a DNA expression cassette comprising a promoter and a DNA subsequence encoding a protein; and
,diluting the complex with a pharmaceutically acceptable excipient. - View Dependent Claims (37, 38)
- lipid complex for systemic administration to a mammal comprising;
Specification